p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

Kudahetti, Sak, Fisher, Gabrielle, Ambroisine, Laurence, Foster, Christopher, Reuter, Victor, Eastham, James, Møller, Henrik, Kattan, Michael W, Cooper, Colin S, Scardino, Peter, Cuzick, Jack and Berney, Daniel M (2009) p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU International, 104 (1). pp. 20-4. ISSN 1464-4096

Full text not available from this repository. (Request a copy)

Abstract

OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P

Item Type: Article
Uncontrolled Keywords: aged,cohort studies,humans,immunohistochemistry,male,middle aged,multivariate analysis,prognosis,prostatic neoplasms,survival analysis,tumor markers, biological,tumor suppressor protein p53
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:00
Last Modified: 21 Apr 2020 22:31
URI: https://ueaeprints.uea.ac.uk/id/eprint/46144
DOI: 10.1111/j.1464-410X.2009.08407.x

Actions (login required)

View Item View Item